Sudan Loganathan
Stock Analyst at Stephens & Co.
(4.30)
# 365
Out of 5,241 analysts
50
Total ratings
64.29%
Success rate
13.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Overweight | $220 | $105.05 | +109.42% | 1 | May 12, 2026 | |
| CPRX Catalyst Pharmaceuticals | Downgrades: Equal-Weight | n/a | $31.23 | - | 3 | May 7, 2026 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.17 | +327.35% | 3 | Mar 31, 2026 | |
| IMNM Immunome | Maintains: Overweight | $33 → $30 | $19.90 | +50.75% | 4 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $95 → $100 | $79.67 | +25.52% | 4 | Mar 2, 2026 | |
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $78.75 | +20.63% | 1 | Dec 17, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $7.90 | +89.87% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $2.02 | +296.04% | 2 | Nov 24, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $8.78 | +70.84% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $11.09 | +62.31% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $39.64 | -11.71% | 1 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $3.22 | +86.34% | 3 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $28.32 | +58.90% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $15.51 | +93.42% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $49.84 | +20.39% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.17 | +152.37% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $4.36 | +244.04% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $19.91 | +402.26% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.22 | +1,539.34% | 1 | May 14, 2024 |
Palvella Therapeutics
May 12, 2026
Initiates: Overweight
Price Target: $220
Current: $105.05
Upside: +109.42%
Catalyst Pharmaceuticals
May 7, 2026
Downgrades: Equal-Weight
Price Target: n/a
Current: $31.23
Upside: -
Actinium Pharmaceuticals
Mar 31, 2026
Reiterates: Overweight
Price Target: $5
Current: $1.17
Upside: +327.35%
Immunome
Mar 4, 2026
Maintains: Overweight
Price Target: $33 → $30
Current: $19.90
Upside: +50.75%
Kymera Therapeutics
Mar 2, 2026
Maintains: Overweight
Price Target: $95 → $100
Current: $79.67
Upside: +25.52%
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $78.75
Upside: +20.63%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $7.90
Upside: +89.87%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $2.02
Upside: +296.04%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $8.78
Upside: +70.84%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $11.09
Upside: +62.31%
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $39.64
Upside: -11.71%
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.22
Upside: +86.34%
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $28.32
Upside: +58.90%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $15.51
Upside: +93.42%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $49.84
Upside: +20.39%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.17
Upside: +152.37%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $4.36
Upside: +244.04%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $19.91
Upside: +402.26%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.22
Upside: +1,539.34%